FDA Clearance Tracker · K214068
Quantia IgE
Last checked: Nov 19, 2026Latest source record: Feb 21, 2023 (this decision)Source: openFDAMethods & limitations
Decided
Feb 21, 2023
Substantially Equivalent
Time to decision
421 days
Received Dec 27, 2021. Calendar days, including time FDA spent waiting on the applicant.
Pathway
510(k)
Special
Device class
Class II
The decision
- FDA number
- K214068
- Device name
- Quantia IgE
- Applicant
- Biokit, S.A.
- Applicant location
- Lliçà D´Amunt, ES
- Received
- Dec 27, 2021
- Decided
- Feb 21, 2023
- Decision
- Substantially Equivalent
- Submission type
- Special
Device type
- Device type
- Ige, Antigen, Antiserum, Control (DGC)
- Device class
- Class II
- Regulation
- 21 CFR 866.5510
- Specialty
- Laboratory Medicine & Pathology
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code DGC. The earliest in FDA's data is K771238, decided Jul 15, 1977.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
- FDA database record for K214068
- 510(k) summary (PDF) · FDA posts these some weeks after the decision, so a recent one may not open yet.
The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.
Other decisions for Biokit, S.A.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K243575 · Decided Feb 12, 2025 · 85 days after receipt
Device type: Enzyme Linked Immunosorbent Assay, Herpes Simplex Virus, Hsv-2 (MYF) · Laboratory Medicine & Pathology
K233605 · Decided Aug 7, 2024 · 272 days after receipt
Device type: Test, Antigen, Nuclear, Epstein-Barr Virus (LLM) · Laboratory Medicine & Pathology
K233606 · Decided Aug 7, 2024 · 272 days after receipt
Device type: Epstein-Barr Virus, Other (LSE) · Laboratory Medicine & Pathology
4 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.